GTB-4550 / GT Biopharma - LARVOL DELTA

GT Biopharma Announces $16 million in Warrant Exercise Proceeds (PRNewswire) - “GT Biopharma…announce the company has raised over $16 million in proceeds from the exercise of warrants…The warrant exercise proceeds along with the funds raised when GT Biopharma up listed to the Nasdaq stock exchange puts the company on solid financial ground to accelerate development of GTBP's drug candidate pipeline. The robust pipeline includes GTB-4550 for lung, lymphoma and other cancers, GTB-5550 for ovarian and prostate cancer, and GTB-6550 for breast and gastric cancer among other drug candidates.”

Financing • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Ovarian Cancer • Prostate Cancer